

CITATION REPORT

List of articles citing

CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response

DOI: 10.1097/ftd.ob013e31817d6f5d
Therapeutic Drug Monitoring, 2008, 30, 474-82.

Source: <https://exaly.com/paper-pdf/44936088/citation-report.pdf>

Version: 2024-04-17


This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
111	Pharmacogenomics of antidepressant drugs. 2009 , 124, 57-73		94
110	Genetic modulation of the pharmacological treatment of pain. 2009 , 124, 168-84		76
109	Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. 2009 , 6, 522-43		90
108	Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. 2009 , 24, 250-6		57
107	Gender differences in antidepressant drug response. 2010 , 22, 485-500		107
106	Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study. 2010 , 62, 193-7		25
105	The promise and reality of pharmacogenetics in psychiatry. 2010 , 30, 931-74		20
104	The promise and reality of pharmacogenetics in psychiatry. 2010 , 33, 181-224		24
103	Pharmacogenetic considerations in the treatment of psychiatric disorders. 2010 , 11, 423-39		22
102	Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. 2011 , 25, 896-907		32
101	Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. 2011 , 12, 365-77		40
100	Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. 2011 , 7, 1101-15		59
99	Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. 2011 , 78, 243-57		102
98	ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. 2011 , 21, 163-70		66
97	Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. 2011 , 12, 631-46		50
96	Pharmacogenetics of antidepressants. 2011 , 2, 6		55
95	Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. 2011 , 215, 367-77		22

94	Sex differences in pharmacokinetics of antidepressants. 2011 , 7, 213-26	42
93	The clinical impact of ABCB1 polymorphisms on the treatment of psychiatric diseases. 2011 , 17, 2843-51	16
92	Pharmacogenetics of antidepressant response. 2011 , 11, 101-25	39
91	Pharmacogenetics of antidepressant response. 2011 , 36, 87-113	112
90	Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). 2012 , 27, 85-105	113
89	Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats. 2012 , 166, 1333-43	34
88	Stress-related depression: neuroendocrine, genetic, and therapeutical aspects. 2012 , 13, 556-68	25
87	Paroxetine for the treatment of depression: a critical update. 2012 , 13, 421-31	84
86	Pharmacogenetics in psychiatry. 53-68	2
85	Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. 2012 , 13, 441-64	37
84	Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. 2012 , 165, 289-312	135
83	Association between the functional polymorphism (C3435T) of the gene encoding P-glycoprotein (ABCB1) and major depressive disorder in the Japanese population. 2012 , 46, 555-9	42
82	ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram. 2013 , 127, 579-86	15
81	P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents. 2013 , 38, 2209-19	34
80	Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. 2013 , 25, 509-33	54
79	Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. 2013 , 162B, 487-520	66
78	Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. 2013 , 13, 1-11	184
77	Pharmacogenetics in major depression: a comprehensive meta-analysis. 2013 , 45, 183-94	148

76	Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. 2013 , 25, 554-71		50
75	Douleur chronique : rôle de la pharmacogénétique dans la résistance aux antidépresseurs. 2013 , 26, 218-225		
74	Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability. 2013 , 16, 2259-72		28
73	Pharmacogenomics in Psychiatric Disorders. 2013 , 191-223		
72	Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex. 2013 , 18, 118-27		48
71	Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. 2014 , 14, 457-62		29
70	Genotype variability and haplotype profile of ABCB1 (MDR1) gene polymorphisms in Macedonian population. 2014 , 35, 121-33		2
69	Association of 2 neurotrophic factor polymorphisms with efficacy of paroxetine in patients with major depressive disorder in a Chinese population. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 612-7	3.2	13
68	Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. 2014 , 14, 176-81		49
67	Drugs, genes and the blues: pharmacogenetics of the antidepressant response from mouse to man. 2014 , 123, 55-76		11
66	Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1H2 genotypes on donepezil clearance. 2014 , 78, 135-44		37
65	Towards the clinical implementation of pharmacogenetics in bipolar disorder. 2014 , 12, 90		21
64	Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. 2014 , 10, 1093-118		12
63	Are there meaningful biomarkers of treatment response for depression?. 2014 , 19, 539-61		47
62	The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. 2014 , 19, 165-75		45
61	From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. 2014 , 59, 62-75		37
60	ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis. 2015 , 168B, 274-83		42
59	Markers of Individual Drug Metabolism: Towards the Development of a Personalized Antidepressant Prescription. 2015 , 16, 17-45		10

58	Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors. 2015 , 11, 1219-32	28
57	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. 2015 , 98, 127-34	488
56	Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors. 2015 , 122, 35-42	18
55	Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. 2015 , 17, 50	55
54	Pharmacogenetics and Antipsychotic Treatment Response/  2015 , 36, 53-67	7
53	A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances. 2015 , 15, 172-6	20
52	Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems. 2015 , 71, 835-41	7
51	Pharmacogenetics and analgesic effects of antidepressants in chronic pain management. 2015 , 12, 163-175	4
50	ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression. 2015 , 15, 332-9	22
49	Psychopathology in Women. 2015 ,	1
48	The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?. 2016 , 17,	7
47	Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. 2016 , 16, 1357-1369	10
46	ABCB1 genotyping in the treatment of depression. 2016 , 17, 2039-2069	24
45	Effect of 24 cytochrome P450 2D6 variants found in the Chinese population on the N-demethylation of amitriptyline in vitro. 2016 , 54, 2475-2479	
44	The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes. 2016 , 1, 431-442	6
43	Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. 2016 , 91, 897-907	51
42	Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies. 2016 , 30, 1169-1189	12
41	A common polymorphism in the ABCB1 gene is associated with side effects of PGP-dependent antidepressants in a large naturalistic Dutch cohort. 2016 , 16, 202-8	7

40	Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways. 2016 , 17, 417-34	11
39	Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study. 2016 , 73, 86-95	39
38	Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain. 2016 , 55, 143-67	12
37	Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms. 2017 , 54, 677-685	14
36	Possibility of Predicting Serotonin Transporter Occupancy From the In Vitro Inhibition Constant for Serotonin Transporter, the Clinically Relevant Plasma Concentration of Unbound Drugs, and Their Profiles for Substrates of Transporters. 2017 , 106, 2345-2356	1
35	Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. 2017 , 16, 1373-1385	8
34	Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study. 2017 , 18, 987-1001	4
33	Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?. 2017 , 13, 259-277	10
32	Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors. 2018 , 41, 677-683	14
31	Genetics of tailored medicine: Focus on CNS drugs. 2018 , 136, 164-169	1
30	Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks. 2018 , 233, 3-14	67
29	1199G>A Polymorphism Affects the Intracellular Accumulation of Antidepressants in LLC-PK1 Recombinant Cell Lines. 2018 , 37, 1055-1060	3
28	Pharmacogenomics and Biomarkers of Depression. 2019 , 250, 101-113	6
27	Sex differences in the pharmacology of itch therapies-a narrative review. 2019 , 46, 122-142	5
26	Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 3: Pharmacokinetic Considerations. 2019 , 25, 34-40	6
25	Pharmacogenomic potential in advanced cancer patients. 2019 , 76, 415-423	3
24	Pharmacokinetics of serotonergic drugs: focus on OCD. 2019 , 15, 261-273	6
23	Genetic variants in major depressive disorder: From pathophysiology to therapy. 2019 , 194, 22-43	37

22	Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder. 2020 , 30, 19-29		4
21	Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression. 2021 , 1305, 231-255		1
20	The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs. 2021 , 9, e00775		0
19	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. 2021 , 22, 561-628		3
18	Affective Disorders and Gender Differences. 2019 , 611-638		3
17	Genetic Polymorphisms of Cytochrome P450 and Antidepressants. 2016 , 533-543		1
16	Does G2677T Polymorphism of the MDR1 Gene Make a Difference in the Therapeutic Response to Paroxetine in Depressed Patients in a Slovakian Population?. 2018 , 24, 3136-3145		3
15	Pharmacogenetics of Antidepressants: from Genetic Findings to Predictive Strategies. 2019 , 4, 33-43		2
14	Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs. 2016 , 18, 313-322		11
13	How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?. 2020 , 11, 491895		10
12	Pharmacogenomics, How to Deal with Different Types of Variants in Next Generation Sequencing Data in the Personalized Medicine Area. 2020 , 10,		2
11	Therapeutic monitoring of psychoactive drugs - antidepressants: a review. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2015 , 159, 35-43	1.7	10
10	Affective Disorders. 2015 , 527-559		
9	Biomarker in der Depressionsbehandlung: mehr als nur Worte?. <i>Zeitschrift Fur Psychiatrie, Psychologie Und Psychotherapie</i> , 2015 , 63, 217-232	0.3	1
8	Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment-free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design. <i>Human Psychopharmacology</i> , 2021 , e2826	2.3	1
7	Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone. 2022 , 14, 1734		0
6	ABCB1 variants and sex affect serotonin transporter occupancy in the brain.		0
5	Pediatric Considerations for Pharmacogenetic Selective Serotonin Reuptake Inhibitors Clinical Decision Support.		0

- 4 CYP2D6 pharmacogenetics and phenoconversion in personalized medicine. **2022**, 18, 769-785
- 3 ABCB1 gene variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta-analysis including results from the CAN-BIND -1 Study.
- 2 Impact of CYP2D6 Genotype on Paroxetine Serum Concentration. **2023**, Publish Ahead of Print,
- 1 Pharmacogenomics in allogeneic hematopoietic stem cell transplantation: Implications on supportive therapies and conditioning regimens. **2023**, 36, 101470